Obseva (NASDAQ:OBSV) was upgraded by research analysts at TheStreet from a “d+” rating to a “c-” rating in a report issued on Thursday.
Other equities analysts have also issued reports about the company. HC Wainwright set a $30.00 price objective on Obseva and gave the stock a “buy” rating in a report on Monday, July 16th. Zacks Investment Research raised Obseva from a “sell” rating to a “buy” rating and set a $15.00 price objective for the company in a report on Wednesday, August 1st. Wedbush set a $34.00 price objective on Obseva and gave the stock a “buy” rating in a report on Wednesday, October 3rd. Leerink Swann started coverage on Obseva in a report on Wednesday, August 15th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Credit Suisse Group started coverage on Obseva in a report on Thursday, July 19th. They issued an “outperform” rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Obseva currently has a consensus rating of “Buy” and a consensus price target of $28.00.
OBSV stock traded up $0.30 on Thursday, reaching $16.30. The company’s stock had a trading volume of 45,087 shares, compared to its average volume of 83,021. Obseva has a 52 week low of $8.79 and a 52 week high of $20.35. The firm has a market capitalization of $656.95 million, a price-to-earnings ratio of -7.24 and a beta of 1.49.
Obseva (NASDAQ:OBSV) last issued its quarterly earnings data on Wednesday, August 8th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.05. On average, sell-side analysts forecast that Obseva will post -1.93 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. VHCP Management II LLC boosted its stake in Obseva by 5.1% during the 2nd quarter. VHCP Management II LLC now owns 2,252,460 shares of the company’s stock valued at $34,102,000 after purchasing an additional 108,617 shares in the last quarter. FMR LLC bought a new position in Obseva during the 2nd quarter valued at $27,254,000. First Manhattan Co. lifted its position in shares of Obseva by 50.9% during the 2nd quarter. First Manhattan Co. now owns 1,508,966 shares of the company’s stock valued at $22,845,000 after acquiring an additional 508,966 shares during the last quarter. Vivo Capital LLC acquired a new stake in shares of Obseva during the 2nd quarter valued at $14,005,000. Finally, Acuta Capital Partners LLC acquired a new stake in shares of Obseva during the 2nd quarter valued at $6,424,000. 68.26% of the stock is owned by hedge funds and other institutional investors.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.